Figure 3
From: Preclinical study of dimebon on β-amyloid-mediated neuropathology in Alzheimer's disease
The in vivo effect of dimebon treatment on Aβ-mediated neuropathology in TgCRND8 mice and the in vitro effect of dimebon on Aβ generation and aggregation. (A) Total Aβ1-40 and Aβ1-42 content in the brain (B) Oligomeric Aβ content in the brain (C) Plasma level of Aβ1-40 and Aβ1-42 from TgCRND8 mice treated with 12 mg/kg/day dimebon for 4 months. (D) and (E) Secreted Aβ1-42 and Aβ1-40 levels in conditioned media from primary neuron culture derived from E15 APP transgenic mice following 20 hours dimebon treatment (dimebon concentrations: 0, 50 nM, 100 nM and 200 nM). (F) The effect of dimebon on Aβ1-42 aggregation in vitro.